| Lung adenocarcinoma promotion by air pollutants W Hill, EL Lim, CE Weeden, C Lee, M Augustine, K Chen, FC Kuan, ... Nature 616 (7955), 159-167, 2023 | 273 | 2023 |
| Antibodies against endogenous retroviruses promote lung cancer immunotherapy KW Ng, J Boumelha, KSS Enfield, J Almagro, H Cha, O Pich, T Karasaki, ... Nature 616 (7957), 563-573, 2023 | 97 | 2023 |
| Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers E Mugarza, F van Maldegem, J Boumelha, C Moore, S Rana, ... Science advances 8 (29), eabm8780, 2022 | 65 | 2022 |
| Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer KB Leszczynska, G Dobrynin, RE Leslie, J Ient, AJ Boumelha, JM Senra, ... Radiotherapy and Oncology 121 (2), 232-238, 2016 | 47 | 2016 |
| An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations J Boumelha, S de Carné Trécesson, EK Law, P Romero-Clavijo, ... Cancer research 82 (19), 3435-3448, 2022 | 33 | 2022 |
| The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance DR Caswell, P Gui, MK Mayekar, EK Law, O Pich, C Bailey, J Boumelha, ... Nature Genetics 56 (1), 60-73, 2024 | 22 | 2024 |
| Facts and hopes on RAS inhibitors and cancer immunotherapy J Boumelha, M Molina-Arcas, J Downward Clinical Cancer Research 29 (24), 5012-5020, 2023 | 4 | 2023 |
| CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer J Boumelha, A de Castro, N Bah, H Cha, S de Carné Trécesson, S Rana, ... Cancer Research 84 (14), 2231-2246, 2024 | 1 | 2024 |
